The established bio/pharmaceutical companies in Europe are expected to maintain their market strength in the United States despite political shifts in the United Kingdom and Europe that may negatively impact academic gene therapy research, according to Alexander Seyf, CEO and co-founder of Autolomous.
"The established companies in Europe, they still have a huge market in [the United States], and we've seen the growth and establishment of these companies expanding their operation to the United States and elsewhere in the world," Seyf stated in a recent interview with Pharmaceutical Technology.
Geopolitical Influences on Pharmaceutical Research
While university-based research programs may face challenges from political changes in Europe, commercial pharmaceutical operations are predicted to experience minimal disruption. This resilience stems from the industry's global nature and established international market presence.
The implementation of the BIOSECURE Act in the United States is prompting European companies to reconsider their global strategy. "So, [because of the BIOSECURE Act], they might actually also consider [expanding] their activities in Asia," Seyf noted, highlighting how regulatory changes in one region can drive strategic shifts in global operations.
UK's Opportunity in Advanced Therapeutics
Seyf expressed optimism about the United Kingdom's potential to strengthen its position in advanced therapeutics. "The UK government gradually, but certainly, they [will] start also realizing they need to put more support through Catapult, cell and gene therapy, and other activities to boost the industry," he explained.
This increased governmental support could create significant opportunities for the UK in the advanced therapeutics space. "[It] is a very ample opportunity for United Kingdom to put itself back in the map for cell and gene therapy and for new medicine," Seyf emphasized.
Business Viability and Global Collaboration
Looking ahead to 2025, industry experts anticipate that business viability and global collaboration will be critical factors for success in the bio/pharmaceutical sector. Companies that can navigate geopolitical complexities while maintaining strong international partnerships are likely to thrive.
The cell and gene therapy segment, in particular, requires robust international collaboration due to the specialized nature of research, manufacturing, and clinical implementation. As regulatory landscapes evolve across different regions, companies must adapt their strategies to ensure continued growth and market access.
For European companies, maintaining strong connections to both American and Asian markets will be essential for long-term success, especially as political and regulatory environments continue to evolve. This balanced approach to global operations may become a defining characteristic of successful bio/pharmaceutical companies in 2025 and beyond.
